查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1585803

腦腫瘤藥物市場：按類型、治療方法、患者年齡層、分銷管道、最終用戶 - 全球預測 2025-2030

Brain Tumor Therapeutics Market by Type (Glioblastoma, Meningioma, Metastatic Brain Tumors), Therapy (Chemotherapy, Gene Therapy, Immunotherapy), Patient Age Group, Distribution Channel, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年腦腫瘤藥物市值為30.3億美元，預計到2024年將達到32.8億美元，複合年成長率為8.24%，到2030年將達到52.8億美元。

腦腫瘤治療市場的範圍和定義包括一系列治療方法，包括藥物、手術干預和放射線治療，旨在管理和潛在治癒腦腫瘤。對這些治療的需求源於腦腫瘤在全球範圍內的日益流行，而這些疾病的複雜性強調了這些疾病需要專門的治療。腦腫瘤藥物的最終用途主要是在醫院、專門的癌症治療中心和研究機構，其重點是患者的即時治療和更有效治療方法的長期研究。影響市場的主要成長要素包括標靶治療和免疫療法等藥物開發的技術進步、製藥公司增加研發投資以及提高對早期診斷和治療方案的認知。潛在的機會在於擴大採用個人化醫療方法和人工智慧的整合，以提高診斷和治療的準確性。然而，治療成本高、監管障礙和臨床試驗複雜性等挑戰對市場成長造成了重大限制。此外，腦腫瘤和血腦障壁的異質性對開發有效的治療方法提出了獨特的科學挑戰。為了克服這些問題，尋找新的治療方法，例如基因療法、基於奈米粒子的藥物傳輸系統以及使用生物標記進行精準醫學，將是創新和研究的最佳領域。這些創新不僅有可能提高治療效果，還可以減少與傳統治療相關的副作用。在旨在擴大產品系列的持續進步和收購的推動下，市場競爭激烈。為了實現成長，相關人員正在關注研發策略夥伴關係，簡化臨床試驗，並創建可擴展的、具有成本效益的解決方案，以滿足各種類型腦腫瘤治療方法中未滿足的需求。

主要市場統計
基準年[2023] 30.3億美元
預測年份 [2024] 32.8億美元
預測年份 [2030] 52.8億美元
複合年成長率（%） 8.24%

市場動態：揭示快速發展的腦腫瘤藥物市場的關鍵市場洞察

供需的動態交互作用正在改變腦腫瘤藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 腦腫瘤和其他神經系統疾病的發生率上升
    • 檢測腫瘤是否存在的測試需求日益成長
    • 分子診斷研究活動
  • 市場限制因素
    • 診斷和治療高成本
  • 市場機會
    • 增加醫療支出和有利的報銷政策
    • 政府提高癌症意識的舉措
  • 市場挑戰
    • 與腦腫瘤藥物相關的副作用

波特五力：駕馭腦瘤藥物市場的策略工具

波特的五力框架是了解腦腫瘤藥物市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解腦腫瘤藥物市場的外部影響

外部宏觀環境因素在塑造腦腫瘤藥物市場的表現動態中發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解腦腫瘤治療藥物市場的競爭狀況

腦腫瘤藥物市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，以應對日益激烈的競爭。

FPNV定位矩陣腦瘤治療市場供應商的績效評估

FPNV定位矩陣是評估腦腫瘤治療市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃腦腫瘤藥物市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對腦腫瘤藥物市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 腦腫瘤和其他神經系統疾病的發生率增加
      • 檢測腫瘤是否存在的檢驗需求增加
      • 分子診斷相關研究活動
    • 抑制因素
      • 診斷和治療費用高
    • 機會
      • 醫療費用上漲和有利的報銷政策
      • 政府提高癌症意識的舉措
    • 任務
      • 與腦腫瘤藥物相關的副作用
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章腦腫瘤藥物市場：依類型

  • 神經膠母細胞瘤
  • 腦膜瘤
  • 轉移性腦瘤
  • 腦下垂體瘤

第7章腦腫瘤藥物市場治療

  • 化療
  • 基因治療
  • 免疫療法
  • 放射治療
  • 標靶治療
  • 組織工程

第8章按患者年齡層分類的腦腫瘤治療藥物市場

  • 成人用
  • 小兒科

第9章腦腫瘤藥物市場：依通路分類

  • 線下藥局
  • 網路藥房

第10章腦腫瘤藥物市場：依最終用戶分類

  • 門診手術中心
  • 醫院
  • 專科診所

第11章美洲腦腫瘤藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太地區腦腫瘤藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲腦腫瘤藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Adcendo ApS
  • AIVITA Biomedical, Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Aura Biosciences, Inc.
  • Bayer AG
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Bristol-Myers Squibb Company
  • CNS Pharmaceuticals, Inc.
  • Curtana Pharmaceuticals
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GE HealthCare Technologies Inc.
  • Gentech, Inc.
  • GlaxoSmithKline PLC
  • Illumina, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co. Inc.
  • Merck KGaA
  • Novartis AG
  • Novocure GmbH
  • Pfizer Inc.
  • Qiagen NV
  • Sanofi SA
  • Siemens Healthcare GmbH
  • Y-mAbs Therapeutics, Inc.
Product Code: MRR-4342CA326550

The Brain Tumor Therapeutics Market was valued at USD 3.03 billion in 2023, expected to reach USD 3.28 billion in 2024, and is projected to grow at a CAGR of 8.24%, to USD 5.28 billion by 2030.

The scope and definition of the brain tumor therapeutics market encompass a range of treatments including pharmaceuticals, surgical interventions, and radiation therapies aimed at managing and potentially curing brain tumors. The necessity for these treatments arises from the increasing prevalence of brain tumors worldwide, underscored by the complex nature of these conditions, requiring specialized treatments. The application and end-use scope of brain tumor therapeutics are primarily in hospitals, specialized cancer treatment centers, and research institutions, where the focus is on both immediate patient care and long-term research into more effective treatments. Key influencing growth factors in the market include technological advancements in drug development, such as targeted therapies and immunotherapies, increased investment in research and development by pharmaceutical companies, and rising awareness about early diagnosis and treatment options. Potential opportunities lie in the growing adoption of personalized medicine approaches and the integration of artificial intelligence for better diagnostic and treatment accuracy. However, challenges such as high treatment costs, regulatory hurdles, and the complexity of clinical trials impose significant limitations on market growth. Furthermore, the heterogeneity of brain tumors and the blood-brain barrier pose specific scientific challenges to developing efficacious treatments. To overcome these, the best areas of innovation and research include exploring novel treatment methods like gene therapy, nanoparticle-based drug delivery systems, and the use of biomarkers for precision medicine. These innovations could not only enhance treatment efficacy but also reduce side effects associated with traditional therapies. The nature of the market is highly competitive, driven by continuous advancements and acquisitions aimed at expanding product portfolios. To harness growth, stakeholders should focus on strategic partnerships for R&D, seek to streamline clinical trials, and invest in scalable, cost-effective therapies that address the unmet needs in treating various types of brain tumors.

KEY MARKET STATISTICS
Base Year [2023] USD 3.03 billion
Estimated Year [2024] USD 3.28 billion
Forecast Year [2030] USD 5.28 billion
CAGR (%) 8.24%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Brain Tumor Therapeutics Market

The Brain Tumor Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidences of brain cancer and other neurological disorders
    • Rising need for tests detecting the presence of tumors
    • Research activities in the molecular diagnostics
  • Market Restraints
    • High cost associated with the diagnosis and treatment
  • Market Opportunities
    • Rising healthcare expenditure and the favorable reimbursement policies
    • Government initiatives for cancer awareness
  • Market Challenges
    • Side effects associated with brain tumor therapeutics

Porter's Five Forces: A Strategic Tool for Navigating the Brain Tumor Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Brain Tumor Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Brain Tumor Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Brain Tumor Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Brain Tumor Therapeutics Market

A detailed market share analysis in the Brain Tumor Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Brain Tumor Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Brain Tumor Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Brain Tumor Therapeutics Market

A strategic analysis of the Brain Tumor Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Brain Tumor Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adcendo ApS, AIVITA Biomedical, Inc., Amgen Inc., AstraZeneca PLC, Aura Biosciences, Inc., Bayer AG, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Bristol-Myers Squibb Company, CNS Pharmaceuticals, Inc., Curtana Pharmaceuticals, Dr. Reddy's Laboratories Ltd., Eisai Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, GE HealthCare Technologies Inc., Gentech, Inc., GlaxoSmithKline PLC, Illumina, Inc., Johnson & Johnson Services, Inc., Merck & Co. Inc., Merck KGaA, Novartis AG, Novocure GmbH, Pfizer Inc., Qiagen N.V., Sanofi S.A., Siemens Healthcare GmbH, and Y-mAbs Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the Brain Tumor Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Glioblastoma, Meningioma, Metastatic Brain Tumors, and Pituitary Tumors.
  • Based on Therapy, market is studied across Chemotherapy, Gene Therapy, Immunotherapy, Radiation Therapy, Targeted Therapy, and Tissue Engineering.
  • Based on Patient Age Group, market is studied across Adult and Pediatric.
  • Based on Distribution Channel, market is studied across Offline Pharmacies and Online Pharmacies.
  • Based on End-User, market is studied across Ambulatory Surgical Centers, Hospitals, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of brain cancer and other neurological disorders
      • 5.1.1.2. Rising need for tests detecting the presence of tumors
      • 5.1.1.3. Research activities in the molecular diagnostics
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with the diagnosis and treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising healthcare expenditure and the favorable reimbursement policies
      • 5.1.3.2. Government initiatives for cancer awareness
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated with brain tumor therapeutics
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Brain Tumor Therapeutics Market, by Type

  • 6.1. Introduction
  • 6.2. Glioblastoma
  • 6.3. Meningioma
  • 6.4. Metastatic Brain Tumors
  • 6.5. Pituitary Tumors

7. Brain Tumor Therapeutics Market, by Therapy

  • 7.1. Introduction
  • 7.2. Chemotherapy
  • 7.3. Gene Therapy
  • 7.4. Immunotherapy
  • 7.5. Radiation Therapy
  • 7.6. Targeted Therapy
  • 7.7. Tissue Engineering

8. Brain Tumor Therapeutics Market, by Patient Age Group

  • 8.1. Introduction
  • 8.2. Adult
  • 8.3. Pediatric

9. Brain Tumor Therapeutics Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Offline Pharmacies
  • 9.3. Online Pharmacies

10. Brain Tumor Therapeutics Market, by End-User

  • 10.1. Introduction
  • 10.2. Ambulatory Surgical Centers
  • 10.3. Hospitals
  • 10.4. Specialty Clinics

11. Americas Brain Tumor Therapeutics Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Brain Tumor Therapeutics Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Brain Tumor Therapeutics Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Adcendo ApS
  • 3. AIVITA Biomedical, Inc.
  • 4. Amgen Inc.
  • 5. AstraZeneca PLC
  • 6. Aura Biosciences, Inc.
  • 7. Bayer AG
  • 8. Becton, Dickinson and Company
  • 9. Bio-Rad Laboratories, Inc.
  • 10. Bristol-Myers Squibb Company
  • 11. CNS Pharmaceuticals, Inc.
  • 12. Curtana Pharmaceuticals
  • 13. Dr. Reddy's Laboratories Ltd.
  • 14. Eisai Inc.
  • 15. Eli Lilly and Company
  • 16. F. Hoffmann-La Roche AG
  • 17. GE HealthCare Technologies Inc.
  • 18. Gentech, Inc.
  • 19. GlaxoSmithKline PLC
  • 20. Illumina, Inc.
  • 21. Johnson & Johnson Services, Inc.
  • 22. Merck & Co. Inc.
  • 23. Merck KGaA
  • 24. Novartis AG
  • 25. Novocure GmbH
  • 26. Pfizer Inc.
  • 27. Qiagen N.V.
  • 28. Sanofi S.A.
  • 29. Siemens Healthcare GmbH
  • 30. Y-mAbs Therapeutics, Inc.

LIST OF FIGURES

  • FIGURE 1. BRAIN TUMOR THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. BRAIN TUMOR THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. BRAIN TUMOR THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. BRAIN TUMOR THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BRAIN TUMOR THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BRAIN TUMOR THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GLIOBLASTOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY MENINGIOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY METASTATIC BRAIN TUMORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PITUITARY TUMORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY OFFLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 238. BRAIN TUMOR THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 239. BRAIN TUMOR THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023